Receives GMP Approval from Health Canada

24 November 2014

BEXIMCO PHARMACEUTICALS LTD.

Beximco Pharma Becomes First Bangladeshi Company toReceive GMP Approval from Health Canada

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that it has received GMP (Good Manufacturing Practices) approval from the Canadian regulatory authority, Health Canada. Beximco Pharma is the first Bangladeshi company to receive GMP accreditation from Health Canada.

This prestigious and notable achievement opens a new marketing opportunity for Beximco Pharma's products in the Canadian market and, similar to many other developed countries, Canada is increasingly promoting access to generic drugs, which offers opportunities for generic drug companies like Beximco Pharma. At the beginning of July, Beximco Pharma facilities also received GMP approval from the Taiwan Food & Drug Authority (TFDA), which is considered to be one of the world's most stringent regulatory agencies, again marking a first time approval for a Bangladeshi company.

Nazmul Hassan, Managing Director of Beximco Pharma, said; "Canada is an important market for Beximco Pharma and this approval marks a significant milestone for the Company, further validating our high standards of quality and compliance practices. This approval builds on our existing presence in key regulated markets and is an important step towards our aspiration to become a global generic drug player.''

Beximco Pharma is certified by the EU regulatory authority, where the Company has been exporting medicines since 2013, and has received approvals from the relevant authorities in Australia, Latin America, Gulf Nations, and South Africa, among others. In addition, Beximco Pharma has won the National Export Trophy (Gold), the highest national accolade for export, a record four times for its outstanding contribution to the country's export.

For further information please visit www.beximco-pharma.com or enquire to: 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.20080

Daniel Stewart & Company (NOMAD and Broker)

Emma Earl

Paul Shackleton

Tel: +44 (0)20 7776 6550

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0)20 3727 1000

Notes to Editors

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,000 employees of the Company.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island, Latin & Central American countries, Middle East, Central Asia, South East Asia, including Singapore, Malaysia, Philippines & Hong Kong, and Europe & Austria.